bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S3 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Authors: Anobile Dario P. , Salaroglio Iris C. , Tabbò Fabrizio , La Vecchia Sofia , Akman Muhlis , Napoli Francesca , Bungaro Maristella , Benso Federica , Aldieri Elisabetta , Bironzo Paolo , Kopecka Joanna , Passiglia Francesco , Righi Luisella , Novello Silvia , Scagliotti Giorgio V. , Riganti Chiara
Published: October 2023

Cell lines used
Supplementary Table S2 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Authors: Anobile Dario P. , Salaroglio Iris C. , Tabbò Fabrizio , La Vecchia Sofia , Akman Muhlis , Napoli Francesca , Bungaro Maristella , Benso Federica , Aldieri Elisabetta , Bironzo Paolo , Kopecka Joanna , Passiglia Francesco , Righi Luisella , Novello Silvia , Scagliotti Giorgio V. , Riganti Chiara
Published: October 2023

Patient features
Supplementary Table S1 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Authors: Anobile Dario P. , Salaroglio Iris C. , Tabbò Fabrizio , La Vecchia Sofia , Akman Muhlis , Napoli Francesca , Bungaro Maristella , Benso Federica , Aldieri Elisabetta , Bironzo Paolo , Kopecka Joanna , Passiglia Francesco , Righi Luisella , Novello Silvia , Scagliotti Giorgio V. , Riganti Chiara
Published: October 2023

Representativeness of Study Participants
Supplementary Figure S9 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Authors: Anobile Dario P. , Salaroglio Iris C. , Tabbò Fabrizio , La Vecchia Sofia , Akman Muhlis , Napoli Francesca , Bungaro Maristella , Benso Federica , Aldieri Elisabetta , Bironzo Paolo , Kopecka Joanna , Passiglia Francesco , Righi Luisella , Novello Silvia , Scagliotti Giorgio V. , Riganti Chiara
Published: October 2023

PD-L1 inhibition does not affect amount and phosphorylation of estrogen receptor α.
Female-derived ERα lowNCI-H1385 and ERα highNCI-H1975 cells, male-derived ERα lowA549 and ERα highNCI-H1650 cells were treated 24 h in the absence (-) or presence (+) of 1 μg/mL atezolizumab (Atezo), a PD-L1 inhibitor, then lysed and analyzed for the indicated proteins in nuclear extracts. TBP is included as control of equal protein loading. The image is representative of one of three experiments.
Supplementary Figure S7 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Authors: Anobile Dario P. , Salaroglio Iris C. , Tabbò Fabrizio , La Vecchia Sofia , Akman Muhlis , Napoli Francesca , Bungaro Maristella , Benso Federica , Aldieri Elisabetta , Bironzo Paolo , Kopecka Joanna , Passiglia Francesco , Righi Luisella , Novello Silvia , Scagliotti Giorgio V. , Riganti Chiara
Published: October 2023

Levels of FSHR and LHR in non-small cell lung cancer cells FSHR (panel a) and LHR (panel b) mRNA, measured by RT-PCR (technical triplicates), in female (F)-derived NCI-H1385 and NCI-H1975 cells, and in male (M)-derived A549 and NCI-H1650 cells. The relative expression of each gene in NCI-H1385 cells was considered 1. Data are means+SD (n=3, biological replicates).
Supplementary Figure S6 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Authors: Anobile Dario P. , Salaroglio Iris C. , Tabbò Fabrizio , La Vecchia Sofia , Akman Muhlis , Napoli Francesca , Bungaro Maristella , Benso Federica , Aldieri Elisabetta , Bironzo Paolo , Kopecka Joanna , Passiglia Francesco , Righi Luisella , Novello Silvia , Scagliotti Giorgio V. , Riganti Chiara
Published: October 2023

Levels of ERβ and ERα target genes in non-small cell lung cancer cells
a. ERβ mRNA, measured by RT-PCR (technical triplicates), in female (F)-derived NCI-H1385 and NCI-H1975 cells, and in male (M)-derived A549 and NCI-H1650 cells. The relative expression of ERβ in NCI-H1385 cells was considered 1. Data are means+SD (n=3). ***p<0.001: NCI-H1975 cells versus NCI-H1385; °°p<0.01: M-derived cells versus mean of F-derived cells (ANOVA). b. Expression of ERβ mRNA, measured by RT-PCR (technical triplicates), plotted versus expression of surface PD-L1, measured by flow cytometry (technical triplicates), in 29 human NSCLC cell lines derived from F or M patients. c. Expression of ERα-target genes CXCL12, IGFBP4 and ABCA3, measured by RT-PCR (technical triplicates). The relative expression of each gene in NCI-H1385 cells was considered 1. Data are means+SD (n=3). *p<0.05, ***p<0.001: NCI-H1975 cells versus NCI-H1385; °p<0.05, °°p<0.01, °°°p<0.001: M-derived cells versus mean of F-derived cells (ANOVA).
Supplementary Figure S2 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Authors: Anobile Dario P. , Salaroglio Iris C. , Tabbò Fabrizio , La Vecchia Sofia , Akman Muhlis , Napoli Francesca , Bungaro Maristella , Benso Federica , Aldieri Elisabetta , Bironzo Paolo , Kopecka Joanna , Passiglia Francesco , Righi Luisella , Novello Silvia , Scagliotti Giorgio V. , Riganti Chiara
Published: October 2023

Immunohistochemical characterization of PD-L1 and ERα in non-small cell lung cancer samples.
a. Representative immunohistochemical images of one NSCLC patient classified as PD-L1low (tumor proportion score, TPS: 60%) and one NSCLC patient classified as PD-L1high (TPS: 90%), according to the internal scale used in our prospective study (see Results section for details). Bar: 20 µm. b. Representative immunohistochemical images of ERα and phospho(Ser118)ERα from one NSCLC patient classified as ERαlow (Histo-score, Hscore: 30 for cytosolic ERα, 90 for nuclear ERα) and one NSCLC patient classified as ERαhigh (Hscore: 270 for cytosolic ERα, 240 for nuclear ERα) in our prospective study. One ER+ (score:3+) and one ER- (0+) breast cancer are included as positive and negative control, respectively. Arrow: normal breast tissue as internal control. Bar: 20 µm. c. Expression of ERα-target genes CXCL12, IGFBP4 and ABCA3, measured by RT-PCR (technical triplicates), in samples from 6 NSCLC classified as ERαlow and in 6 NSCLC classified as ERαhigh according to ERα mRNA and protein levels. The same genes were assessed in an ER+ and in an ER-breast cancer, chosen as positive or negative controls, respectively. The mean relative expression of each gene in ERαlow tumors was considered 1. Data are means+SD (n=6). ***p<0.001: ERα high NSCLC tumors versus ERα low NSCLC tumors; °°°p<0.001: ER+breast cancer versus ERα low NSCLC tumors.
Supplementary Figure S14 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Authors: Anobile Dario P. , Salaroglio Iris C. , Tabbò Fabrizio , La Vecchia Sofia , Akman Muhlis , Napoli Francesca , Bungaro Maristella , Benso Federica , Aldieri Elisabetta , Bironzo Paolo , Kopecka Joanna , Passiglia Francesco , Righi Luisella , Novello Silvia , Scagliotti Giorgio V. , Riganti Chiara
Published: October 2023

Effects of letrozole on the efficacy of chemo-immuno-therapy in non-small cell lung cancer xenografts.
1×106 female-derived ERα lowNCI-H1385 cells and ERα highNCI-H1975 cells, male-derived ERα lowA549 cells and ERα highNCI-H1650 cells were implanted subcutaneously (s.c.) in Hu-CD34+NSG mice. When tumors reached the volume of 100 mm3, mice (n= 5/group) were randomized in the following groups: 1) Vehicle group, treated intraperitoneally (i.p.) with 100 µl saline solution (days 1, 7, 14, 21, 28, 35 after randomization); 2) cisplatin (PT) group, treated with 2 mg/kg intravenously (i.v.) (days 7, 14, 21, 28, 35); 3) cisplatin + pembrolizumab (PT+Pemb) group, treated with 2 mg/kg cisplatin i.v. (days 7, 14, 21, 28, 35) and 10 mg/kg i.p. of 100 µl saline solution of pembrolizumab (day 1) followed by 5 mg/kg i.p. (days 7, 14, 21, 28, 35); 4) cisplatin + pembrolizumab + letrozole (PT+Pemb+Letr) group, treated with 2 mg/kg cisplatin i.v. (days 7, 14, 21, 28, 35), 10 mg/kg i.p. of 100 µl saline solution of pembrolizumab (day 1) followed by 5 mg/kg i.p. (days 7, 14, 21, 28, 35) and 1 mg/kg per os of 100 µl saline solution of letrozole daily (days 1-35). Tumor growth was monitored daily with a caliper. Mice were euthanized on day 40. Data are mean volumes+SD. **p<0.01, ***p<0.001: treatments group versus Vehicle group (day 40); °°°p<0.001: PT+Pemb+Letr group versus Pemb+Letr group (day 40; ANOVA).
Supplementary Figure S10 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Authors: Anobile Dario P. , Salaroglio Iris C. , Tabbò Fabrizio , La Vecchia Sofia , Akman Muhlis , Napoli Francesca , Bungaro Maristella , Benso Federica , Aldieri Elisabetta , Bironzo Paolo , Kopecka Joanna , Passiglia Francesco , Righi Luisella , Novello Silvia , Scagliotti Giorgio V. , Riganti Chiara
Published: October 2023

Dose-dependent effects of fulvestrant and letrozole.
ERα highNCI-H1975 cells were grown 24 h in fresh medium (Ctrl) or in medium containing 0.1, 1, 10 nM fluvestrant (Fulv, panel a), an ERα inhibitor, or 0.1, 1, 10 nM letrozole (Letr, panel b), an aromatase inhibitor. As read-out assays, the expression of ERα-target gene CXCL12 was measured by RT-PCR in triplicate (panel a), the amount of 17-β-estradiol was measured by ELISA (technical duplicate, panel b). The relative expression in Ctrl cells was considered 1. Data are means+SD (n=3, biological replicates). *p<0.05, ***p<0.001: treated cells versus Ctrl cells (ANOVA).
Supplementary Figure S1 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Authors: Anobile Dario P. , Salaroglio Iris C. , Tabbò Fabrizio , La Vecchia Sofia , Akman Muhlis , Napoli Francesca , Bungaro Maristella , Benso Federica , Aldieri Elisabetta , Bironzo Paolo , Kopecka Joanna , Passiglia Francesco , Righi Luisella , Novello Silvia , Scagliotti Giorgio V. , Riganti Chiara
Published: October 2023

Outcome of non-small cell lung cancer patients, disaggregated according to gender, PD-L1 and ERα levels. Best response (PD: progressive disease; PR: partial response; SD: stable disease) after 6 months from the beginning of pembrolizumab treatment as first-line monotherapy, PFS and OS (Kapan-Meier and log-rank test) were analyzed in 35 NSCLC patients (15 females; 20 males). a-c. Female (F) and male (M) patients were stratified in CD274/PD-L1low and CD274/PD-L1high, according to the median value of the CD274/PD-L1mRNA, measured by RT-PCR in the tumor samples (technical triplicates). d-f. F and M patients were stratified in ESR1/ERαlow and ESR1/ERαhigh, according to the median value of the ESR1/ERα mRNA, measured by RT-PCR in the tumor samples (technical triplicates).
Supplementary Figure S1 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
Authors: Dermawan Josephine K. , Kelly Ciara , Gao Zhidong , Smith Shaleigh , Jadeja Bhumika , Singer Samuel , Tap William D. , Chi Ping , Antonescu Cristina R.
Published: October 2023

Supplementary Figure 1. Traditional risk stratification in primary gastric and small bowel GIST.
Primary gastric (A-C) and small bowel (D-F) GISTs localized at diagnosis without prior neoadjuvant treatment are risk stratified into low, moderate, and high risk groups based on site, tumor size and mitotic rate using the Miettinen (also includes very low risk) (A, D), Fletcher (B, E) and Joensuu (C, F) risk stratification schemes (Miettinen 2006, Fletcher 2002, Joensuu 2008). Recurrence-free survival for patients in each of these risk groups is represented by Kaplan-Meier curves (global log-rank P) for all primary localized cases.
Supplementary table 1 from Unique Spectrum of Activating BRAF Alterations in Prostate Cancer
Authors: Chehrazi-Raffle Alex , Tukachinsky Hanna , Toye Eamon , Sivakumar Smruthy , Schrock Alexa B. , Bergom Hannah E. , Ebrahimi Hedyeh , Pal Sumanta , Dorff Tanya , Agarwal Neeraj , Mahal Brandon A. , Oxnard Geoffrey R. , Hwang Justin , Antonarakis Emmanuel S.
Published: October 2023

Supplementary table 1
Supplementary Data 1 from Unique Spectrum of Activating BRAF Alterations in Prostate Cancer
Authors: Chehrazi-Raffle Alex , Tukachinsky Hanna , Toye Eamon , Sivakumar Smruthy , Schrock Alexa B. , Bergom Hannah E. , Ebrahimi Hedyeh , Pal Sumanta , Dorff Tanya , Agarwal Neeraj , Mahal Brandon A. , Oxnard Geoffrey R. , Hwang Justin , Antonarakis Emmanuel S.
Published: October 2023

Supplementary Data
Supplementary Data 1 from SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma
Authors: Liu Xian-De , Zhang Yan-Ting , McGrail Daniel J. , Zhang Xuesong , Lam Truong , Hoang Anh , Hasanov Elshad , Manyam Ganiraju , Peterson Christine B. , Zhu Haifeng , Kumar Shwetha V. , Akbani Rehan , Pilie Patrick G. , Tannir Nizar M. , Peng Guang , Jonasch Eric
Published: October 2023

Supplementary Data
Supplementary Table S8 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Table S8. Annotation for the biotypes of DE transcriptome between low and high TIILs subtypes.
Supplementary Table S5 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Table S5. DE genes in C2 (High) compared with C3 (Moderate).
Supplementary Table S2 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Table S2. PCR primers of the 10 genes in the subnetwork for mouse model.
Supplementary Table S17 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Table S17. CD4+/CD8+ T cells infiltration levels in tumor tissues of mice bearing with S180.
Supplementary Table S16 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Table S16. Cell types determination based on different annotation references.
Supplementary Table S14 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Table S14. Top 30 hub genes in the PPI network.
Supplementary Table S13 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Table S13. Univariate and multivariable Cox regression analysis of nodes involved in the prognostics related ceRNA network.
Supplementary Figure S8 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Figure S8. Investigation of the effects of nodes in the subnetwork on TME of SARC.
Supplementary Figure S6 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Figure S6. Construction of subnetwork of prognosis-related ceRNA network.
Supplementary Material 1 from Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Authors: Draghi Arianna , Presti Mario , Jensen Agnete W.P. , Chamberlain Christopher A. , Albieri Benedetta , Rasmussen Anne-Christine K. , Andersen Mads H. , Crowther Michael D. , Svane Inge Marie , Donia Marco
Published: October 2023

Supplementary Figures and Tables
Supplementary Data 3 from Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Authors: Draghi Arianna , Presti Mario , Jensen Agnete W.P. , Chamberlain Christopher A. , Albieri Benedetta , Rasmussen Anne-Christine K. , Andersen Mads H. , Crowther Michael D. , Svane Inge Marie , Donia Marco
Published: October 2023

CD4+ TILs can exert cytotoxicity against JAK1KO MHCIIConst+ tumors even in absence of IFNγ stimulation (TCL#17)
Supplementary Figure S4 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Figure S4. Construction of global ceRNA network between low and high TIILs SARC subtypes.
Supplementary Figure S2 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Figure S2. Validation of subtypes of SARC using Consensus clustering analysis.
Supplementary Figure S1 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Authors: Leng Dongliang , Yang Ziyi , Sun Heng , Song Chengcheng , Huang Chen , Ip Ka U. , Chen Guokai , Deng Chu-Xia , Zhang Xiaohua Douglas , Zhao Qi
Published: October 2023

Supplementary Figure S1. Classification and validation of subtypes of SARC.
Table S1 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Authors: Fukushima Hiroshi , Furusawa Aki , Kato Takuya , Wakiyama Hiroaki , Takao Seiichiro , Okuyama Shuhei , Choyke Peter L. , Kobayashi Hisataka
Published: October 2023

Supplementary Table S1. List of key resource identifiers in this study.
Figure S8 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Authors: Fukushima Hiroshi , Furusawa Aki , Kato Takuya , Wakiyama Hiroaki , Takao Seiichiro , Okuyama Shuhei , Choyke Peter L. , Kobayashi Hisataka
Published: October 2023

Supplementary Fig. S8. Multiplex immunohistochemistry (IHC) of hIL-15-MC38 or parental MC38 tumors four days after CD44-targeted NIR-PIT.
Figure S7 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Authors: Fukushima Hiroshi , Furusawa Aki , Kato Takuya , Wakiyama Hiroaki , Takao Seiichiro , Okuyama Shuhei , Choyke Peter L. , Kobayashi Hisataka
Published: October 2023

Supplementary Fig. S7. Host tumor immunity two days after CD44-targeted NIR-PIT against hIL-15-MC38 or MC38 tumors.
Figure S4 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Authors: Fukushima Hiroshi , Furusawa Aki , Kato Takuya , Wakiyama Hiroaki , Takao Seiichiro , Okuyama Shuhei , Choyke Peter L. , Kobayashi Hisataka
Published: October 2023

Supplementary Fig. S4. Comparison of immune cell expressions between hIL-15-MC38 and MC38 tumors.
Figure S13 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Authors: Fukushima Hiroshi , Furusawa Aki , Kato Takuya , Wakiyama Hiroaki , Takao Seiichiro , Okuyama Shuhei , Choyke Peter L. , Kobayashi Hisataka
Published: October 2023

Supplementary Fig. S13. Expressions of CD8+ T, NK, and NKT cells in untreated left tumors after CD44-targeted NIR-PIT using a bilateral tumor mouse model (R: hIL-15-MC38 tumor, L: MC38 tumor).
Figure S11 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Authors: Fukushima Hiroshi , Furusawa Aki , Kato Takuya , Wakiyama Hiroaki , Takao Seiichiro , Okuyama Shuhei , Choyke Peter L. , Kobayashi Hisataka
Published: October 2023

Supplementary Fig. S11. In vitro CD44-targeted NIR-PIT in Pan02-luc cells.
Figure S10 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Authors: Fukushima Hiroshi , Furusawa Aki , Kato Takuya , Wakiyama Hiroaki , Takao Seiichiro , Okuyama Shuhei , Choyke Peter L. , Kobayashi Hisataka
Published: October 2023

Supplementary Fig. S10. Immunohistochemical evaluation of immune cell infiltration in MC38 and Pan02-luc tumors.
Figure S1 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Authors: Fukushima Hiroshi , Furusawa Aki , Kato Takuya , Wakiyama Hiroaki , Takao Seiichiro , Okuyama Shuhei , Choyke Peter L. , Kobayashi Hisataka
Published: October 2023

Supplementary Fig. S1. Host immune responses after intraperitoneal or intratumoral injection of IL-15.
Figure S5 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Authors: Habault Justine , Schneider Jeffrey A. , Ha Susan , Ruoff Rachel , Pereira Luiza D. , Puccini Joseph , Ranieri Michela , Ayasun Ruveyda , Deng Jiehui , Kasper Amanda C. , Bar-Sagi Dafna , Wong Kwok-Kin , Zoubeidi Amina , Claessens Frank , Wise David R. , Logan Susan K. , Kirshenbaum Kent , Garabedian Michael J.
Published: October 2023

Model for MPC309 effect on AR-dependent gene expression
Figure S4 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Authors: Habault Justine , Schneider Jeffrey A. , Ha Susan , Ruoff Rachel , Pereira Luiza D. , Puccini Joseph , Ranieri Michela , Ayasun Ruveyda , Deng Jiehui , Kasper Amanda C. , Bar-Sagi Dafna , Wong Kwok-Kin , Zoubeidi Amina , Claessens Frank , Wise David R. , Logan Susan K. , Kirshenbaum Kent , Garabedian Michael J.
Published: October 2023

PK of MPC309 and effects of MPC309 on immune cells
Supplementary Fig. S3 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Authors: Pradhan Anjan K. , Modi Jinkal , Maji Santanu , Kumar Amit , Bhoopathi Praveen , Mannangatti Padmanabhan , Guo Chunqing , Afosah Daniel K. , Mochel Mark C. , Mukhopadhyay Nitai D. , Kirkwood John M. , Wang Xiang-Yang , Desai Umesh R. , Sarkar Devanand , Emdad Luni , Das Swadesh K. , Fisher Paul B.
Published: October 2023

MDA-9 downregulation impacted the invasiveness of patient derived melanoma cells
Figure S3 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Authors: Habault Justine , Schneider Jeffrey A. , Ha Susan , Ruoff Rachel , Pereira Luiza D. , Puccini Joseph , Ranieri Michela , Ayasun Ruveyda , Deng Jiehui , Kasper Amanda C. , Bar-Sagi Dafna , Wong Kwok-Kin , Zoubeidi Amina , Claessens Frank , Wise David R. , Logan Susan K. , Kirshenbaum Kent , Garabedian Michael J.
Published: October 2023

Effects of MPC309 versus ethisterone on gene expression in LNCaP-abl cells
Supplementary Fig. S1 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Authors: Pradhan Anjan K. , Modi Jinkal , Maji Santanu , Kumar Amit , Bhoopathi Praveen , Mannangatti Padmanabhan , Guo Chunqing , Afosah Daniel K. , Mochel Mark C. , Mukhopadhyay Nitai D. , Kirkwood John M. , Wang Xiang-Yang , Desai Umesh R. , Sarkar Devanand , Emdad Luni , Das Swadesh K. , Fisher Paul B.
Published: October 2023

Analytical data for IVMT-Rx-3
Supplementary Data from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Authors: Pradhan Anjan K. , Modi Jinkal , Maji Santanu , Kumar Amit , Bhoopathi Praveen , Mannangatti Padmanabhan , Guo Chunqing , Afosah Daniel K. , Mochel Mark C. , Mukhopadhyay Nitai D. , Kirkwood John M. , Wang Xiang-Yang , Desai Umesh R. , Sarkar Devanand , Emdad Luni , Das Swadesh K. , Fisher Paul B.
Published: October 2023

Supplementary Information for IVMT-Rx-3 Synthesis
Supplementary Data from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Authors: Pradhan Anjan K. , Modi Jinkal , Maji Santanu , Kumar Amit , Bhoopathi Praveen , Mannangatti Padmanabhan , Guo Chunqing , Afosah Daniel K. , Mochel Mark C. , Mukhopadhyay Nitai D. , Kirkwood John M. , Wang Xiang-Yang , Desai Umesh R. , Sarkar Devanand , Emdad Luni , Das Swadesh K. , Fisher Paul B.
Published: October 2023

Supplementary Figure Legends
Supplementary Table S1 from A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells
Authors: Venkateswaran Geetha , McDonald Paul C. , Chafe Shawn C. , Brown Wells S. , Gerbec Zachary J. , Awrey Shannon J. , Parker Seth J. , Dedhar Shoukat
Published: October 2023

Supplementary Table S1 lists the shRNA sequences used to knock down gene expression of SLC1A5, GLS1 and GCLC in cancer cells.
Supplementary Figure S6 from A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells
Authors: Venkateswaran Geetha , McDonald Paul C. , Chafe Shawn C. , Brown Wells S. , Gerbec Zachary J. , Awrey Shannon J. , Parker Seth J. , Dedhar Shoukat
Published: October 2023

Supplementary Figure S6 shows IHC staining for 4-HNE in SUM159PT tumors, demonstrating that co-targeting CAIX/XII activity and GSH synthesis increases lipid peroxidation in vivo.
Supplementary Figure S3 from A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells
Authors: Venkateswaran Geetha , McDonald Paul C. , Chafe Shawn C. , Brown Wells S. , Gerbec Zachary J. , Awrey Shannon J. , Parker Seth J. , Dedhar Shoukat
Published: October 2023

Supplementary Figure S3 shows heatmaps showing the drug combination responses for cytotoxicity of cancer cells in hypoxia induced by SLC-0111 in combination with inhibition of Gln metabolism.
Supplementary Figure S2 from A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells
Authors: Venkateswaran Geetha , McDonald Paul C. , Chafe Shawn C. , Brown Wells S. , Gerbec Zachary J. , Awrey Shannon J. , Parker Seth J. , Dedhar Shoukat
Published: October 2023

Supplementary Figure S2 shows that CAIX catalytic activity and the CAIX intracellular domain regulate Gln uptake by hypoxic cancer cells.
Supplementary Figure S1 from A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells
Authors: Venkateswaran Geetha , McDonald Paul C. , Chafe Shawn C. , Brown Wells S. , Gerbec Zachary J. , Awrey Shannon J. , Parker Seth J. , Dedhar Shoukat
Published: October 2023

Supplementary Figure S1 shows data describing the characterization of the interaction between SLC1A5 and CAIX in cancer cells.
Supplementary Table S1 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
Authors: Kong Chao , Pu Junyi , Zhao Qianqian , Weng Weining , Ma Linjie , Qian Yu , Hu Wenhao , Meng Xun , Meng Tao
Published: October 2023

Supplementary Table S1 shows the amino acid sequences of h6M24, SC16 and hM30
Supplementary Fig.S9 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
Authors: Kong Chao , Pu Junyi , Zhao Qianqian , Weng Weining , Ma Linjie , Qian Yu , Hu Wenhao , Meng Xun , Meng Tao
Published: October 2023

Supplementary Fig.S9 shows hematology and serum chemistry of MTX-13 in monkey
Supplementary Fig.S6 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
Authors: Kong Chao , Pu Junyi , Zhao Qianqian , Weng Weining , Ma Linjie , Qian Yu , Hu Wenhao , Meng Xun , Meng Tao
Published: October 2023

Supplementary Fig.S6 shows PTK7 is an actionable target in small cell lung cancer
Supplementary Fig.S4 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
Authors: Kong Chao , Pu Junyi , Zhao Qianqian , Weng Weining , Ma Linjie , Qian Yu , Hu Wenhao , Meng Xun , Meng Tao
Published: October 2023

Supplementary Fig.S4 shows MTX-13 cellular dynamics and bystander killing effect
Supplementary Table S4 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Authors: Meric-Bernstam Funda , Calvo Emiliano , Lee Keun Seok , Moreno Victor , Park Yeon Hee , Rha Sun Young , Chalasani Pavani , Zhong Wei , Zhou Li , Pirie-Shepherd Steven , Leung Abraham C.F. , Curigliano Giuseppe
Published: October 2023

Supplementary Table S4 shows the immunogenicity results
Supplementary Table S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Authors: Meric-Bernstam Funda , Calvo Emiliano , Lee Keun Seok , Moreno Victor , Park Yeon Hee , Rha Sun Young , Chalasani Pavani , Zhong Wei , Zhou Li , Pirie-Shepherd Steven , Leung Abraham C.F. , Curigliano Giuseppe
Published: October 2023

Supplementary Table S3 shows the biomarker results
Supplementary Table S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Authors: Meric-Bernstam Funda , Calvo Emiliano , Lee Keun Seok , Moreno Victor , Park Yeon Hee , Rha Sun Young , Chalasani Pavani , Zhong Wei , Zhou Li , Pirie-Shepherd Steven , Leung Abraham C.F. , Curigliano Giuseppe
Published: October 2023

Supplementary Table S1 shows the treatment-related adverse events
Supplementary File 1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Authors: Meric-Bernstam Funda , Calvo Emiliano , Lee Keun Seok , Moreno Victor , Park Yeon Hee , Rha Sun Young , Chalasani Pavani , Zhong Wei , Zhou Li , Pirie-Shepherd Steven , Leung Abraham C.F. , Curigliano Giuseppe
Published: October 2023

Supplementary File 1 shows the Methods and Results for Part 1B
Supplementary Figure S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Authors: Meric-Bernstam Funda , Calvo Emiliano , Lee Keun Seok , Moreno Victor , Park Yeon Hee , Rha Sun Young , Chalasani Pavani , Zhong Wei , Zhou Li , Pirie-Shepherd Steven , Leung Abraham C.F. , Curigliano Giuseppe
Published: October 2023

Supplementary Figure S3 shows the time to and duration of response in patients with confirmed CR or PR (the mITT population)
Supplementary Tables 1-2, Supplementary Figures 1-7 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP
Authors: Hu Jiajia , Huang Runjie , Liang Chengcai , Wang Yingnan , Wang Min , Chen Yanxing , Wu Chenyi , Zhang Jinling , Liu Zekun , Zhao Qi , Liu Zexian , Wang Feng , Yuan Shuqiang
Published: October 2023

Supplementary Tables 1-2, Supplementary Figures 1-7
Supplementary Table 3 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP
Authors: Hu Jiajia , Huang Runjie , Liang Chengcai , Wang Yingnan , Wang Min , Chen Yanxing , Wu Chenyi , Zhang Jinling , Liu Zekun , Zhao Qi , Liu Zexian , Wang Feng , Yuan Shuqiang
Published: October 2023

The raw data of 1C
Supplementary Table 1 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP
Authors: Hu Jiajia , Huang Runjie , Liang Chengcai , Wang Yingnan , Wang Min , Chen Yanxing , Wu Chenyi , Zhang Jinling , Liu Zekun , Zhao Qi , Liu Zexian , Wang Feng , Yuan Shuqiang
Published: October 2023

The primer sequences used.
Figure S7 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP
Authors: Hu Jiajia , Huang Runjie , Liang Chengcai , Wang Yingnan , Wang Min , Chen Yanxing , Wu Chenyi , Zhang Jinling , Liu Zekun , Zhao Qi , Liu Zexian , Wang Feng , Yuan Shuqiang
Published: October 2023

Figure S7: TOPFLASH analysis of JUP in TRIM50 overexpressing versus control empty vector 293T cells.
Figure S6 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP
Authors: Hu Jiajia , Huang Runjie , Liang Chengcai , Wang Yingnan , Wang Min , Chen Yanxing , Wu Chenyi , Zhang Jinling , Liu Zekun , Zhao Qi , Liu Zexian , Wang Feng , Yuan Shuqiang
Published: October 2023

Figure S6: Immunoblotting analysis of JUP in TRIM50 overexpressing versus control empty vector MKN45 cells.
Figure S5 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP
Authors: Hu Jiajia , Huang Runjie , Liang Chengcai , Wang Yingnan , Wang Min , Chen Yanxing , Wu Chenyi , Zhang Jinling , Liu Zekun , Zhao Qi , Liu Zexian , Wang Feng , Yuan Shuqiang
Published: October 2023

Figure S5: 293T cells were transfected with Myc-TRIM50 plasmid, Flag-JUP plasmid and HA-Ub plasmid, whole-cell lysates were subjected to SDS denaturation and immunoprecipitation with JUP antibody and immunoblot analysis with the indicated antibodies.
Figure S3 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP
Authors: Hu Jiajia , Huang Runjie , Liang Chengcai , Wang Yingnan , Wang Min , Chen Yanxing , Wu Chenyi , Zhang Jinling , Liu Zekun , Zhao Qi , Liu Zexian , Wang Feng , Yuan Shuqiang
Published: October 2023

Figure S3A: Tumor photograph in the nude mouse subcutaneous xenograft model by implanting TRIM50 overexpressing (TRIM50) versus control empty vector (EV) MKN45 cells (n = 6 mice per group). Scale bar: 1 cm
Figure S3B: MKN74 cells were transfected with lentiviruses expressing TRIM50 shRNA. A universal nonsilencing shRNA was used as a negative control (sh-NC). Whole-cell lysates were subjected to immunoblot analysis with TRIM50 antibody.
Figure S3C: Tumor photograph in the nude mouse subcutaneous xenograft model by implanting TRIM50 knockdown (TRIM50 sh-1/TRIM50 sh-2) versus control (TRIM50 sh-NC) MKN74 cells (n = 6 mice per group). Scale bar: 1 cm
Figure S2 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP
Authors: Hu Jiajia , Huang Runjie , Liang Chengcai , Wang Yingnan , Wang Min , Chen Yanxing , Wu Chenyi , Zhang Jinling , Liu Zekun , Zhao Qi , Liu Zexian , Wang Feng , Yuan Shuqiang
Published: October 2023

Figure S2: Immunoblotting assay of TRIM50 expression in GC cells.
Figure S1 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP
Authors: Hu Jiajia , Huang Runjie , Liang Chengcai , Wang Yingnan , Wang Min , Chen Yanxing , Wu Chenyi , Zhang Jinling , Liu Zekun , Zhao Qi , Liu Zexian , Wang Feng , Yuan Shuqiang
Published: October 2023

Figure S1A: The expression of TRIM50 and UBE2QL1 in the Cancer Genome Atlas (TCGA) database.
Figure S1B: The IHC score of Figure 1F.
Supplementary Figure 9 from Nrf2 Drives Hepatocellular Carcinoma Progression through Acetyl-CoA–Mediated Metabolic and Epigenetic Regulatory Networks
Authors: Xi Caixia , Pang Junfeng , Barrett Amanda , Horuzsko Anatolij , Ande Satyanarayana , Mivechi Nahid F. , Zhu Xingguo
Published: October 2023

S9. MYC silencing reduced the expression of glycolysis genes in HepG2 cells.
Table S3 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Authors: Khella Christen A. , Franciosa Lucyann , Rodirguez-Rodriguez Lorna , Rajkarnikar Resha , Mythreye Karthikeyan , Gatza Michael L.
Published: October 2023

Summary of differentially expressed proteins (RPPA analysis) following HCK silencing in CAOV3 cells
Supplementary Figure 6 from Nrf2 Drives Hepatocellular Carcinoma Progression through Acetyl-CoA–Mediated Metabolic and Epigenetic Regulatory Networks
Authors: Xi Caixia , Pang Junfeng , Barrett Amanda , Horuzsko Anatolij , Ande Satyanarayana , Mivechi Nahid F. , Zhu Xingguo
Published: October 2023

S6. A glucose dependency of NRF2 regulation in HepG2 cells.
Table S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Authors: Khella Christen A. , Franciosa Lucyann , Rodirguez-Rodriguez Lorna , Rajkarnikar Resha , Mythreye Karthikeyan , Gatza Michael L.
Published: October 2023

CAOV3 RPPA data summary
Fig S3 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Authors: Khella Christen A. , Franciosa Lucyann , Rodirguez-Rodriguez Lorna , Rajkarnikar Resha , Mythreye Karthikeyan , Gatza Michael L.
Published: October 2023

Cell line selection and engineering
Supplementary Figure 2 from Nrf2 Drives Hepatocellular Carcinoma Progression through Acetyl-CoA–Mediated Metabolic and Epigenetic Regulatory Networks
Authors: Xi Caixia , Pang Junfeng , Barrett Amanda , Horuzsko Anatolij , Ande Satyanarayana , Mivechi Nahid F. , Zhu Xingguo
Published: October 2023

S2. Nrf2 ablation affects gene expression in mouse liver tumors.
Fig S1 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Authors: Khella Christen A. , Franciosa Lucyann , Rodirguez-Rodriguez Lorna , Rajkarnikar Resha , Mythreye Karthikeyan , Gatza Michael L.
Published: October 2023

Distribution of clinical features associated with poor and good prognostic HGSOC patient samples in the TCGA U133A dataset.
Supplementary Materials and Methods from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Authors: Blanchard Zannel , Rush Craig M. , Arnesen Spencer , Vahrenkamp Jeffery M. , Rodriguez Adriana C. , Jarboe Elke A. , Brown Callie , Chang Matthew E.K. , Flory Mark R. , Mohammed Hisham , Modzelewska Katarzyna , Lum David H. , Gertz Jason
Published: October 2023

Supplementary Materials and Methods
Supplemental Table 5 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Authors: Blanchard Zannel , Rush Craig M. , Arnesen Spencer , Vahrenkamp Jeffery M. , Rodriguez Adriana C. , Jarboe Elke A. , Brown Callie , Chang Matthew E.K. , Flory Mark R. , Mohammed Hisham , Modzelewska Katarzyna , Lum David H. , Gertz Jason
Published: October 2023

Enrichment values for ER associating proteins in endometrial and breast cancer cell lines
Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Authors: Blanchard Zannel , Rush Craig M. , Arnesen Spencer , Vahrenkamp Jeffery M. , Rodriguez Adriana C. , Jarboe Elke A. , Brown Callie , Chang Matthew E.K. , Flory Mark R. , Mohammed Hisham , Modzelewska Katarzyna , Lum David H. , Gertz Jason
Published: October 2023

Overlap between prolonged E2 treatment and differentially expressed genes in vitro
Supplemental Figure 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Authors: Blanchard Zannel , Rush Craig M. , Arnesen Spencer , Vahrenkamp Jeffery M. , Rodriguez Adriana C. , Jarboe Elke A. , Brown Callie , Chang Matthew E.K. , Flory Mark R. , Mohammed Hisham , Modzelewska Katarzyna , Lum David H. , Gertz Jason
Published: October 2023

ER mutants do not affect proliferation, but down-regulate proteins associated with movement and impact migration
Supplementary Figure 7 from Continuous Administration of Anti-VEGFA Antibody Upregulates PAI-1 Secretion from Ovarian Cancer Cells via miR-143-3p Downregulation
Authors: Yagi Taro , Sawada Kenjiro , Miyamoto Mayuko , Shimizu Aasa , Oi Yukako , Toda Aska , Nakamura Koji , Kinose Yasuto , Kodama Michiko , Hashimoto Kae , Kimura Tadashi
Published: October 2023

Supplementary Figure 7 shows that the transduction of miR-143-3p did not affect tumor growth in a murine model of ovarian cancer.
Supplementary Figure 5 from Continuous Administration of Anti-VEGFA Antibody Upregulates PAI-1 Secretion from Ovarian Cancer Cells via miR-143-3p Downregulation
Authors: Yagi Taro , Sawada Kenjiro , Miyamoto Mayuko , Shimizu Aasa , Oi Yukako , Toda Aska , Nakamura Koji , Kinose Yasuto , Kodama Michiko , Hashimoto Kae , Kimura Tadashi
Published: October 2023

Supplementary Figure 5 shows thatVEGF induces in vitro tube formation in HUVECs at a concentration of ≥ 3 ng/ml, whereas treatment with 100 µg/ml anti-VEGFA antibody attenuates the effects of VEGF.
Supplementary Figure 3 from Continuous Administration of Anti-VEGFA Antibody Upregulates PAI-1 Secretion from Ovarian Cancer Cells via miR-143-3p Downregulation
Authors: Yagi Taro , Sawada Kenjiro , Miyamoto Mayuko , Shimizu Aasa , Oi Yukako , Toda Aska , Nakamura Koji , Kinose Yasuto , Kodama Michiko , Hashimoto Kae , Kimura Tadashi
Published: October 2023

Supplementary Figure 3 shows the correlation analysis between miR-10a-5p expression and PAI-1 concentration.
Supplementary Table 4 from Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer
Authors: Chen Yonghong , Dufour Catherine R. , Han Lingwei , Li Ting , Xia Hui , Giguère Vincent
Published: October 2023

Supplementary Table 4. Source data.
Supplementary Figure 1 from Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination–Deficient Leukemia Cells
Authors: Sullivan-Reed Katherine , Toma Monika M. , Drzewiecka Malgorzata , Nieborowska-Skorska Margaret , Nejati Reza , Karami Adam , Wasik Mariusz A. , Sliwinski Tomasz , Skorski Tomasz
Published: October 2023

S1. Genetic aberrations and mRNA expression variabilities of POLQ, PARP1 and RAD52 do not coexist in 519 AML samples from the BEAT-AML cohort.
Supplementary Table 3 from Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer
Authors: Chen Yonghong , Dufour Catherine R. , Han Lingwei , Li Ting , Xia Hui , Giguère Vincent
Published: October 2023

Supplementary Table 3. List of reagents, plasmids, antibodies, and human RT-qPCR primers used in this study.
Supplementary Table 2 from Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer
Authors: Chen Yonghong , Dufour Catherine R. , Han Lingwei , Li Ting , Xia Hui , Giguère Vincent
Published: October 2023

Supplementary Table 2. RNA-seq analysis of LNCaP mTOR KD cells rescued with mTOR or empty vector (EV) control ± R1881 for 24h.
Supplementary Table 1 from Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer
Authors: Chen Yonghong , Dufour Catherine R. , Han Lingwei , Li Ting , Xia Hui , Giguère Vincent
Published: October 2023

Supplementary Table 1. RNA-seq analysis of LNCaP HOXB13 KD cells rescued with HOXB13 WT, HOXB13 phospho-deficient mutant 3A, or empty vector (EV) control ± R1881 for 24h.
Supplementary Figure 6 from Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer
Authors: Chen Yonghong , Dufour Catherine R. , Han Lingwei , Li Ting , Xia Hui , Giguère Vincent
Published: October 2023

Supplementary Figure 6 (Panels 1-11). Uncropped blots.
Supplementary Figure 3 from Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer
Authors: Chen Yonghong , Dufour Catherine R. , Han Lingwei , Li Ting , Xia Hui , Giguère Vincent
Published: October 2023

Supplementary Figure 3. SKP2 is an E3 ligase for HOXB13.
Supplementary Figure 1 from Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer
Authors: Chen Yonghong , Dufour Catherine R. , Han Lingwei , Li Ting , Xia Hui , Giguère Vincent
Published: October 2023

Supplementary Figure 1. mTOR negatively regulates HOXB13 protein stability
Supplemental Figure 6 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
Authors: Jiang Haowen , He Clifford Jiajun , Li Albert M. , He Bo , Li Yang , Zhou Meng-Ning , Ye Jiangbin
Published: October 2023

S6. Mitochondrial uncoupling inhibits reductive carboxylation in ccRCC cells.
Supplemental Figure 5 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
Authors: Jiang Haowen , He Clifford Jiajun , Li Albert M. , He Bo , Li Yang , Zhou Meng-Ning , Ye Jiangbin
Published: October 2023

S5. Mitochondrial uncoupler NEN, FCCP and BAM15 inhibit reductive carboxylation under hypoxia.
Supplemental Figure 3 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
Authors: Jiang Haowen , He Clifford Jiajun , Li Albert M. , He Bo , Li Yang , Zhou Meng-Ning , Ye Jiangbin
Published: October 2023

S3. Mitochondrial uncoupler FCCP and BAM5 inhibit reductive carboxylation.
Supplementary Table 7 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Authors: Zhang Shenghua , Zhang Zheng , Liu Xiaolong , Deng Yibin , Zheng Jian , Deng Jieqiong , Wang Yirong , Guo Binbin , Li Fanrong , Chen Xiaoyue , Pan Yacheng , Wang Jieyu , Lu Jiachun , Wu Siqi , Guo Qiang , Zhou Yifeng
Published: October 2023

Homer Known Motif Enrichment Results (GATA_peaks_on_LINC00887_Promoter_motif)
Supplementary Table 6 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Authors: Zhang Shenghua , Zhang Zheng , Liu Xiaolong , Deng Yibin , Zheng Jian , Deng Jieqiong , Wang Yirong , Guo Binbin , Li Fanrong , Chen Xiaoyue , Pan Yacheng , Wang Jieyu , Lu Jiachun , Wu Siqi , Guo Qiang , Zhou Yifeng
Published: October 2023

The genomic position of the predicted ORFs of the six lncRNAs
Supplementary Table 5 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Authors: Zhang Shenghua , Zhang Zheng , Liu Xiaolong , Deng Yibin , Zheng Jian , Deng Jieqiong , Wang Yirong , Guo Binbin , Li Fanrong , Chen Xiaoyue , Pan Yacheng , Wang Jieyu , Lu Jiachun , Wu Siqi , Guo Qiang , Zhou Yifeng
Published: October 2023

Sequences of LINC00887 and ACLY-BP cDNA
Supplementary Table 4 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Authors: Zhang Shenghua , Zhang Zheng , Liu Xiaolong , Deng Yibin , Zheng Jian , Deng Jieqiong , Wang Yirong , Guo Binbin , Li Fanrong , Chen Xiaoyue , Pan Yacheng , Wang Jieyu , Lu Jiachun , Wu Siqi , Guo Qiang , Zhou Yifeng
Published: October 2023

Sequences of shRNAs and siRNAs used in this study